Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined Effects of Mutation and Ionic Strength on α-Synuclein Reveal Generic Features of Aggregation-Prone Monomeric States.

ACS chemical neuroscience·2026
Same author

Diagnostic Methods for Clinical Lumbar Instability: A Systematic Review of Current Status, Challenges, and Future Directions.

Cureus·2026
Same author

Evidence-Based Diagnostic and Therapeutic Methods for Thoracic Outlet Syndrome: A Systematic Review.

Cureus·2026
Same author

Correction to "Synthesis of Reversible Sequence-Defined Oligourethane Macrocycles through Click and Declick Thiol-Amine Conjugation with a Meldrum's Acid Derived Conjugate Acceptor".

The Journal of organic chemistry·2026
Same author

Validity and Prognostic Value of the UCSD Dyspnea Questionnaire in Fibrotic Hypersensitivity Pneumonitis: A Multicenter Prospective Study.

Annals of the American Thoracic Society·2026
Same author

Prognostic Impact of Quantitative CT Disease Extent and Pattern in Fibrotic Hypersensitivity Pneumonitis.

Annals of the American Thoracic Society·2026

Related Experiment Video

Updated: May 31, 2026

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

Early α-Synuclein Heterodimerization Kinetics Predict Parkinson's Disease Onset.

Sachin Chaudhary1, Vaishnavi Tammara2,3, Bhargavi Choudhary4

  • 1Department of Chemistry, Indian Institute of Science Education and Research, Pune, Maharashtra 411008, India.

The Journal of Physical Chemistry. B
|May 28, 2026
PubMed
Summary

The time it takes for wild-type and mutant alpha-synuclein (αS) to form heterodimers predicts Parkinson's disease onset age. Early aggregation dynamics, not late-stage stability, may drive disease progression.

More Related Videos

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

Related Experiment Videos

Last Updated: May 31, 2026

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

Area of Science:

  • Biochemistry
  • Neuroscience
  • Computational Biology

Background:

  • Protein aggregation, particularly of alpha-synuclein (αS), is central to Parkinson's disease pathogenesis.
  • Linking physicochemical properties of protein aggregation to clinical outcomes like age of onset remains a significant challenge.

Purpose of the Study:

  • To investigate if simulated aggregation dynamics of αS can predict the clinical age of onset in Parkinson's disease.
  • To identify specific aggregation events and timescales that correlate with disease initiation.

Main Methods:

  • Utilized a multiscale simulation framework combining coarse-grained (CG) and atomistic simulations.
  • Quantified early dimerization kinetics and estimated dimer interaction energies for wild-type and familial mutant αS.
  • Calculated CG thermodynamic protofilament binding free energies and complemented with atomistic calculations.

Main Results:

  • The timescale of wild-type and mutant αS heterodimer formation significantly predicted Parkinson's disease age of onset.
  • Homodimer formation kinetics and heterodimer protofilament binding affinities showed no predictive power.
  • Homodimer protofilament binding free energies correlated moderately, suggesting late-stage fibril stability is not the primary determinant of disease initiation.

Conclusions:

  • Early-stage oligomeric dynamics, specifically heterodimer formation timescales, are crucial predictors of clinical Parkinson's disease phenotypes.
  • Disease initiation appears to be governed by a two-stage aggregation process, emphasizing the role of early events.
  • Findings highlight the importance of considering aggregation kinetics over static fibril stability in understanding neurodegenerative diseases.